General References



Faber E, Mojzikova R, Plachy R et al. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. Leuk Res 2010; 34:91-3.

Faber P, Barnes G, Srinidhi J et al. Huntingtin interacts with a family of WW domain proteins. Hum Molec Genet 1998; 7:1463-74.

Fabiani E, D’Alò F, Scardocci A et al. Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res 2009; 33:1068-71.

Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21:978-85.

Fabris B, Bortoletto M, Candido R et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J Hypertens 2005; 23:309-16.

Fabris C, Vandelli C, Toniutto P et al. Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Gastroenterol Hepatol 2011; 26:328-33.

Fabris M, Quartuccio L, Lombardi S et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2010. doi:10. 1016/j. autrev. 2010. 06. 012.

Facciolà G, Avenoso A, Scordo MG et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999; 21:341-5.

Facchinetti F, Fasolato C, del Giudice E et al. Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage. Neurobiol Aging 2006; 27:218-27.

Factor SA, Steenland NK, Higgins DS et al. Postural instability/gait disturbance in Parkinson’s disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry 2011; 82:564-8.

Facheris MF, Schneider NK, Lesnick TG et al. Coffee, caffeine-related genes, and Parkinson’s disease: a case-control study. Mov Disord 2008; 23:2033-40.

Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W. The neuronal 5-HT3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007; 560:1-8.

Faeste CK, Ivanova L, Uhlig S. In vitro metabolism of the mycotoxin enniatin B in different species and CYP P450 reaction phenotyping. Drug Metab Dispos 2011; 39:1768-76.

Fagan AM, Christopher E, Taylor JW et al. ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer’s disease-like cerebral amyloidosis. Am J Pathol 2004; 165:1413-22.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67:993-1006.

Fagerholm R, Hofstetter B, Tommiska J et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40:844-53.

Fagerholm U. Prediction of human pharmacokinetics-gut-wall metabolism. J Pharm Pharmacol 2007; 59:1335-43.

Fagoonee S, Hobbs RM, de Chiara L et al. Generation of functional hepatocytes from mouse germ line cell-derived pluripotent stem cells in vitro. Stem Cells Dev 2010; 19:1183-94.

Fahmi OA, Boldt S, Kish M, Obach RS, Tremaine LM. Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008; 36:1971-4.

Fahmi OA, Hurst S, Plowchalk D et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009; 37:1658-66.

Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008; 36:1698-708.

Fairbrother KS, Grove J, de Waziers I et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8:543-52.

Fairfax BP, Davenport EE, Makino S, Hill AV, Vannberg FO, Knight JC. A common haplotype of the TNF receptor 2 gene modulates endotoxin tolerance. J Immunol 2011; 186:3058-65.

Faisel F, Romppanen EL, Hiltunen M et al. Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation. Eur J Hum Genet 2004; 12:187-91.

Fajac A, Gligorov J, Rezai K et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 2010; 103:560-6.

Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971-80.

Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993; 16:1254-61.

Fajardo G, Zhao M, Powers J, Bernstein D. Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. J Mol Cell Cardiol 2006; 40:375-83.

Fakhoury M, Andreu-Gallien J, Mahr A et al. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J Clin Pharmacy and therapeutics 2007; 6:633-9.

Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn’s disease. Inflamm Bowel Dis 2006; 12:745-9.

Fakhoury M, Litalien C, Medard Y et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005; 33:1603-7.

Fakkert IE, Jansen L, Meijer K et al. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. Breast Cancer Res Treat 2011; 129:157-64.

Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009; 20:615-20.

Falik-Zaccai TC, Laskar M, Kfir N, Nasser W, Slor H, Khayat M. Cockayne syndrome type II in a Druze isolate in Northern Israel in association with an insertion mutation in ERCC6. Am J Med Genet A 2008; 146:1423-9.

Falus A, Fenyő M, Eder K, Madarasi A. Genome-wide gene expression study indicates the anti-inflammatory effect of polarized light in recurrent childhood respiratory disease. Inflamm Res 2011; 60:965-72.

Falvella FS, Galvan A, Frullanti E et al. Transcription deregulation at the 15q25 locus in association with lung adenocarcinoma risk. Clin Cancer Res 2009; 15:1837-42.

Falzoi M, Mossa A, Congeddu E, Saba L, Pani L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. Pharmacogenomics 2010; 11:559-71.

Fallah S, Seifi M, Firoozrai M, Ghohari LH, Samadikuchaksaraei A, Samadirad B. Effect of apolipoprotein E genotypes on incidence and development of coronary stenosis in Iranian patients with coronary artery disease. J Clin Lab Anal 2011; 25:43-6.

Fallo F, Bertello C, Tizzani D et al. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. J Hypertens 2011; 29:1773-7.

Fan AZ, Yesupriya A, Chang MH et al. Gene polymorphisms in association with emerging cardiovascular risk markers in adult women. BMC Med Genet 2010; 11:6.

Fan BJ, Wang DY, Tham CC, Lam DS, Pang CP. Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci 2008; 49:1886-97.

Fan HM, Wang Z, Feng FM et al. Association of TNF-alpha-238G/A and 308 G/A gene polymorphisms with pulmonary tuberculosis among patients with coal worker’s pneumoconiosis. Biomed Environ Sci 2010; 23:137-45.

Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther 2009; 330:389-402.

Fan J, Maeng HJ, Du Y, Kwan D, Pang KS. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. Eur J Pharm Sci 2011; 42:19-29.

Fan J, Stukas S, Wong C et al. An ABCA1-independent pathway for recycling of a poorly lipidated 8. 1 nm apolipoprotein E particle from glia. J Lipid Res 2011; 52:1605-16.

Fan L, Wang G, Wang LS et al. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin 2007; 28:1685-92.

Fan L, Wang JC, Jiang F et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 2009; 65:403-9.

Fan L, Zhang W, Guo D et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2008; 83:471-6.

Fan LQ, Hardy DO, Catterall JF, Zhao J, Li SX. Identification and characterization of an androgen-responsive Kap promoter enhancer located in the intron II region of human angiotensinogen gene. J Steroid Biochem Mol Biol 2010; 119:135-40.

Fan M, Liu B, Jiang T, Jiang X, Zhao H, Zhang J. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr Genet 2010; 20:1-7.

Fan X, Wang Y, Sun K et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin Pharmacol Ther 2007; 82:187-96.

Fan Y, Tao JH, Zhang LP, Li LH, Ye DQ. Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 2011; 38:4445-53.

Fancello T, Dardis A, Rosano C et al. Molecular analysis of NPC1 and NPC2 gene in 34 Niemann-Pick C Italian patients: identification and structural modeling of novel mutations. Neurogenetics 2009; 10:229-39.

Fanelli M, Filippi E, Sentinelli F et al. The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers 2005; 21:175-80.

Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D Jr, Glue PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy 2008; 28:42-50.

Fang D, Bao Y, Li X et al. Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 2010; 56:9-16.

Fang HL, Strom SC, Ellis E et al. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J Pharmacol Exp Ther 2007; 323:586-98.

Fang HM, Xu JM, Mei Q et al. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Acta Pharmacol Sin 2009; 30:1566-72.

Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997; 17:227-33.

Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359:147-51.

Fang J, Coutts RT, McKenna KF, Baker GB. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:592-9.

Fang J, McKay G, Song J, Remillrd A, Li X, Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos 2001; 29:1638-43.

Fang S, Miao J, Xiang L, Ponugoti B, Treuter E, Kemper JK. Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism. Mol Cell Biol 2007; 27:1407-24.

Fang W, Geng X, Deng Y et al. Platelet activating factor induces blood brain barrier permeability alteration in vitro. J Neuroimmunol 2011; 230:42-7.

Fang Y, van Meurs JBJ, d’Alesio A et al. Promoter and 3-prime-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am J Hum Genet 2005; 77:807-23.

Fang ZZ, Zhang YY, Ge GB et al. Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions. Phytother Res 2011; 25:256-63.

Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 2010; 69:193-9.

Fanous AH, Chen X, Wang X et al. Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families. Am J Med Genet B Neuropsychiatr Genet 2009; 150:411-7.

Fanous AH, van den Oord EJ, Riley BP et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005; 162:1824-32.

Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007; 64:772-84.

Fanta S, Jönsson S, Karlsson MO et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J Clin Pharmacol 2010; 50:581-97.

Fanta S, Niemi M, Jönsson S et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008; 18:77-90.

Faouzi S, Medzihradszky KF, Hefner C, Maher JJ, Correia MA. Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97? Biochemistry 2007; 46:7793-803.

Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010; 17:356-62.

Farabegoli F, Papi A, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates EGFR, MMP-2, MMP-9 EMMPRIN and inhibits the invasion of MCF-7 tamoxifen resistant cells. Biosci Rep 2010; 31:99-108.

Faraday N, Becker DM, Becker LC. Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 2007; 8:1413-25.

Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006; 67:13-20.

Faratian D, Zweemer AJ, Nagumo Y et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 2011; 17:4451-61.

Fargher EA, Tricker K, Newman W et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 2:187-95.

Farheen S, Sengupta S, Santra A et al. Gilbert’s syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene. World J Gastroenterol 2006; 12:2269-75.

Farid NA, Jakubowski JA, Payne CD et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009; 25:1821-9.

Farid NA, Payne CD, Small DS et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81:735-41.

Farinola N, Piller NB. CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? Pharmacogenomics 2007; 8:151-8.

Farlow M, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. Pharmacogenomics J 2004; 4:332-5.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer’s disease trial. Arch Neurol 2003; 60:843-8.

Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 2003; 42:1383-92.

Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology 1998; 50:669-77.

Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000; 23:197-213.

Farnebo L, Jedlinski A, Ansell A et al. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 2009; 24:549-56.

Farquhar C, Rowland-Jones S, Mbori-Ngacha D et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses 2004; 20:692-7.

Farré M, Abanades S, Roset PN et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 2007; 323:954-62.

Farrer L, Conneally P. A genetic model for age at onset in Huntington disease. Am J Hum Genet 1985; 37:350-7.

Farrer L, Cupples L, Wiater P, Conneally P, Gusella J, Myers R. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am J Hum Genet 1993; 53:125-30

Farris SD, Hu JH, Krishnan R et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: Role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 2011; 286:22665-77.

Fasching PA, Kollmannsberger B, Strissel PL et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol 2008; 134:1079-86.

Fasullo M, Chen Y, Bortcosh W, Sun M, Egner PA. Aflatoxin B(1)-associated DNA adducts stall S phase and stimulate Rad51 foci in Saccharomyces cerevisiae. J Nucleic Acids 2010. doi:10. 4061/2010/456487.

Fatih N, Camberlein E, Island ML et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med 2010; 88:477-86.

Fatini C, Abbate R, Pepe G et al. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J 2000; 21:633-8.

Fatini C, Sticchi E, Marcucci R et al. S38G single-nucleotide polymorphism at the KCNE1 locus is associated with heart failure. Heart Rhythm 2010; 7:363-7.

Fattinger K, Funk C, Pantze M et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69:223-31.

Fattinger K, Meier-Abt A. Interactions of phytotherapeutic drugs, foods and drinks with medicines. Ther Umsch 2002; 59:292-300.

Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 2001; 29:1123-9.

Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006; 317:1200-9.

Faucette SR, Wang H, Hamilton GA et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004; 32:348-58.

Faucette SR, Zhang TC, Moore R et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320:72-80.

Fava C, Montagnana M, Almgren P et al. Association between adducin-1 G460W variant and blood pressure in Swedes is dependent on interaction with body mass index and gender. Am J Hypertens 2007; 20:981-9.

Fava C, Montagnana M, Almgren P et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 2008; 52:373-80.

Fava C, Montagnana M, Almgren P et al. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. J Hypertens 2010; 28:294-9.

Favis R, Sun Y, van de Velde H et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 2011; 21:121-9.

Favre C, Monti JA, Scapini C, Pellegrino J, Carnovale CE, Carrillo MC. Putrescine decreases cytochrome P450 3A4 levels during liver regeneration in the rat. J Hepatol 1998; 28:700-8.

Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. J Clin Pharmacol 2001; 41:305-16.

Fayuk D, Yakel JL. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol 2004; 66:658-66.

Fayz S, Inaba T. Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 1998; 42:1654-8.

Fazili IS, Jiang W, Wang L et al. Persistent induction of cytochrome P4501A1 in human hepatoma cells by 3-methylcholanthrene: evidence for sustained transcriptional activation of the CYP1A1 promoter. J Pharmacol Exp Ther 2010; 333:99-109.

Féart C, Torrès MJ, Samieri C et al. Adherence to a Mediterranean diet and plasma fatty acids: data from the Bordeaux sample of the Three-City study. Br J Nutr 2011; 106:149-58.

Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer 2009; 115:3046-57.

Fecteau KA, Eiler H, Oliver JW. Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells. Am J Vet Res 2011; 72:675-80.

Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. In: Pagon RA, Bird TD, Dolan CR, Stephens K (Eds). GeneReviews. University of Washington, Seattle, 1993-2003. Available from: http://www. ncbi. nlm. nih. gov/books/NBK1409/

Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001; 93:571-6.

Feghhi M, Nikzamir A, Esteghamati A, Farahi F, Nakhjavani M, Rashidi A. The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes. Diabetes Res Clin Pract 2008; 81:1-4.

Fehér A, Juhász A, Rimanóczy A, Kálmán J, Janka Z. Association study of interferon-γ, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease. Am J Geriatr Psychiatry 2010; 18:983-7.

Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75:1-18.

Feidt DM, Klein K, Hofmann U et al. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 2010; 38:1589-97.

Feidt DM, Klein K, Nüssler A, Zanger UM. RNA-interference approach to study functions of NADPH: cytochrome P450 oxidoreductase in human hepatocytes. Chem Biodivers 2009; 6:2084-91.

Feierman DE. The effect of paracetamol (acetaminophen) on fentanyl metabolism in vitro. Acta Anaesthesiol Scand 2000; 44:560-3.

Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996; 24:932-9.

Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 2003; 27:981-8.

Feierman DE, Melnikov Z, Zhang J. The paradoxical effect of acetaminophen on CYP3A4 activity and content in transfected HepG2 cells. Arch Biochem Biophys 2002; 398:109-17.

Feig JE, Pineda-Torra I, Sanson M et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010; 120:4415-24.

Feik E, Baierl A, Hieger B et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 2010; 21:91-7.

Feinshtein V, Holcberg G, Amash A et al. Nitrofurantoin transport by placental choriocarcinoma JAr cells: involvement of BCRP, OATP2B1 and other MDR transporters. Arch Gynecol Obstet 2010; 281:1037-44.

Feitosa MF, An P, Ordovas JM et al. Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis 2011; 215:435-9.

Feitsma H, Kuiper RV, Korving J, Nijman IJ, Cuppen E. Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. Cancer Res 2008; 68:5059-66.

Feldman AM. The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann Thorac Surg 2003; 76:2246-53.

Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005; 2:475-83.

Feldweg AM, Leddy JP. Drug Interactions Affecting the Efficacy of Corticosteroid Therapy A Brief Review with An Illustrative Case. J Clin Rheumatol 1999; 5:143-150.

Felix CA, Walker AH, Lange BJ et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95:13176-81.

Felix K, Rockwood LD, Pretsch W et al. Moderate G6PD deficiency increases mutation rates in the brain of mice. Free Radic Biol Med 2002; 32:663-73.

Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008; 36:435-41.

Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-6.

Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-7.

Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry 2007; 12:264-72.

Feng BJ, Sun LD, Soltani-Arabshahi R et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009. doi:10. 1371/journal. pgen. 1000606.

Feng C, Yamashita F, Hashida M. Automated extraction of information from the literature on chemical-CYP3A4 interactions. J Chem Inf Model 2007; 47:2449-55.

Feng DD, Zhang H, Zhang P et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med 2011; 15:2164-75.

Feng J, Sobell JL, Heston LL, Cook EH Jr, Goldman D, Sommer SS. Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid. Am J Med Genet 1998; 81:172-8.

Feng J, Sun X, Sun N et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin 2009; 41:429-35.

Feng J, Zheng J, Gelernter J et al. An in-frame deletion in the alpha(2C) adrenergic receptor is common in African-Americans. Mol Psychiatry 2001; 6:168-72.

Feng Y, Cameron MD, Frackowiak B et al. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Bioorg Med Chem Lett 2007; 17:2355-60.

Feng Y, Niu T, Xing H et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004; 75:112-21.

Fenton RA, Smith CP, Knepper MA. Role of collecting duct urea transporters in the kidney-insights from mouse models. J Membr Biol 2006; 212:119-31.

Fenty-Stewart N, Park JY, Roth SM et al. Independent and combined influence of AGTR1 variants and aerobic exercise on oxidative stress in hypertensives. Blood Press 2009; 18:204-12.

Fenyo IM, Florea IC, Raicu M, Manea A. Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice. Vascul Pharmacol 2011; 54:100-6.

Fer M, Corcos L, Dréano Y et al. Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J Lipid Res 2008; 49:2379-89.

Ferder N, Eby CS, Deych E et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2010; 8:95-100.

Ferdinands JM, Mannino DM, Gwinn ML, Bray MS. ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study. PLoS One 2007. doi:10. 1371/journal. pone. 0000289.

Ferdinandusse S, Denis S, Hogenhout EM et al. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 2007; 28:904-12.

Ferguson C, Miksys S, Palmour R, Tyndale RF. Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African Green Monkeys. Drug Metab Dispos 2011. doi:10. 1124/dmd. 111. 040378.

Ferguson JF, Phillips CM, McMonagle J et al. NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. Atherosclerosis 2010; 211:539-44.

Ferguson JF, Phillips CM, Tierney AC et al. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr 2010; 91:794-801.

Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR. IL23R and IL12B SNPs and Haplotypes Strongly associate with Crohn’s disease risk in a New Zealand population. Gastroenterol Res Pract 2010; 2010:539461.

Ferguson LR, Huebner C, Petermann I et al. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol 2008; 14:4652-61.

Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. Genes, diet and inflammatory bowel disease. Mutat Res 2007; 622:70-83.

Ferguson RJ, de Morais SM, Benhamou S et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-61.

Ferlin A, Bartoloni L, Rizzo G, Roverato A, Garolla A, Foresta C. Androgen receptor gene CAG and GGC repeat lengths in idiopathic male infertility. Mol Hum Reprod 2004; 10:417-21.

Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C. Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 2010; 17:17-25.

Ferlin A, Garolla A, Bettella A et al. Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism. Eur J Endocrinol 2005; 152:419-25.

Fernandes BJ, Miranda Silva CD, Andrade JM, Matthes AD, Coelho EB, Lanchote VL. Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. Cancer Chemother Pharmacol 2011; 68:897-904.

Fernandes Filho JA, Vedeler CA, Myhr KM, Nyland H, Pandey JP. TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity 2002; 35:377-80.

Fernandes Gdos S, Blanke CD, Freitas D, Guedes R, Hoff PM. Perioperative treatment of gastrointestinal stromal tumors. Oncology 2009; 23:54-61.

Fernandes HB, Catches JS, Petralia RS et al. High-affinity kainate receptor subunits are necessary for ionotropic but not metabotropic signaling. Neuron 2009; 63:818-29.

Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002; 22:326-9.

Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, Martinez-Murillo R. Nitric oxide: target for therapeutic strategies in Alzheimer’s disease. Curr Pharm Des 2010; 16:2837-50.

Fernández P, Trzaska S, Wilder T et al. Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am J Pathol 2008; 172:1675-82.

Fernández RM, Boru G, Pecina A et al. Ancestral RET haplotype associated with Hirschsprung’s disease shows linkage disequilibrium breakpoint at -1249. J Med Genet 2005; 42:322-7.

Fernández-Cruz ML, Valdehita A, Alonso M, Mann E, Herradón B, Navas JM. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation product pifithrin-β. Life Sci 2011; 88:774-83.

Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22:86-92.

Fernández-Novoa L, Lombardi V, Fondevila M, Seoane S, Cacabelos R. Association study of M129V polymorphism at the PRNP gene in Alzheimer disease. Am J Med Genet 2002; 114:829-30.

Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85:1334-9.

Fernández-Real JM, Casamitjana R, Ricart-Engel W. Leptin is involved in gender-related differences in insulin sensitivity. Clin Endocrinol 1998; 49:505-11.

Fernandez-Reyes D, Craig AG, Kyes SA et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997; 6:1357-60.

Fernández-Rubio A, López-Cima MF, González-Arriaga P et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 2008; 61:309-16.

Fernandez-Salguero P, Hoffman SM, Cholerton S et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57:651-60.

Fernando H, Davydov DR, Chin CC, Halpert JR. Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W. Arch Biochem Biophys 2007; 460:129-40.

Fernando H, Halpert JR, Davydov DR. Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job’s titration. Biochemistry 2006; 45:4199-209.

Fernando H, Halpert JR, Davydov DR. Kinetics of electron transfer in the complex of cytochrome P450 3A4 with the flavin domain of cytochrome P450BM-3 as evidence of functional heterogeneity of the heme protein. Arch Biochem Biophys 2008; 471:20-31.

Fernando MM, Stevens CR, Sabeti PC, et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet 2007. doi:10. 1371/journal. pgen. 0030192.

Ferrándiz-Huertas C, Fernández-Carvajal A, Ferrer-Montiel A. Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells. Int J Cancer 2011; 128:192-205.

Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-9.

Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22:633-58.

Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med 2008; 86:685-90.

Ferreira PE, Veiga MI, Cavaco I et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 2008; 30:10-5.

Ferreiro A, Monnier N, Romero NB et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002; 51:750-9.

Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9:1543-6.

Ferrera P, Arias C. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Neurochem Int 2005; 47:589-96.

Ferreri F, Agbokou C, Gauthier S. Cardiovascular effects of cholinesterase inhibitors in Alzheimer’s disease. Rev Neurol 2007; 163:968-74.

Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol 2011; 9:88.

Ferrettini C, Pirulli D, Cosseddu D et al. Molecular analysis of the AGXT gene in Italian patients with primary hyperoxaluria type 1 (PH1). J Nephrol 1998; 11 Suppl 1:18-22.

Ferrini JB, Pichard L, Domergue J, Maurel P. Long-term primary cultures of adult human hepatocytes. Chem Biol Interact 1997; 107:31-45.

Ferris SH. Evaluation of memantine for the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2003; 4:2305-13.

Fertleman CR, Baker MD, Parker KA et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006; 52:767-74.

Fester L, Prange-Kiel J, Jarry H, Rune GM. Estrogen synthesis in the hippocampus. Cell Tissue Res 2011; 345:285-94.

Fetisova EK, Avetisyan AV, Izyumov DS, Korotetskaya MV, Chernyak BV, Skulachev VP. Mitochondria-targeted antioxidant SkQR1 selectively protects MDR (Pgp 170)-negative cells against oxidative stress. FEBS Lett 2010; 584:562-6.

Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009; 66:1169-79.

Feyereisen R. Molecular biology of insecticide resistance. Toxicol Lett 1995; 82-83:83-90.

Fialho RN, Martins L, Pinheiro JP et al. Role of human leukocyte antigen, killer-cell immunoglobulin-like receptors, and cytokine gene polymorphisms in leptospirosis. Hum Immunol 2009; 70:915-20.

Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002; 41:1195-211.

Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109:178-83.

Fidlerova J, Kleiblova P, Bilek M et al. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother Pharmacol 2010; 65:661-9.

Fiegenbaum M, da Silveira FR, van der Sand CR et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78:551-8.

Fiegenbaum M, da Silveira FR, van der Sand CR et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta 2005; 362:182-8.

Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res 2010; 51:1407-15.

Field JJ, Singh AJ, Kanakkanthara A, Halafihi T, Northcote PT, Miller JH. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the Tongan marine sponge Cacospongia mycofijiensis. J Med Chem 2009; 52:7328-32.

Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60:925-54.

Figueroa JD, Malats N, García-Closas M et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008; 29:1955-62.

Filigheddu F, Argiolas G, Degortes S et al. Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 2010; 11:319-25.

Filigheddu F, Reid JE, Troffa C et al. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004; 4:154-60.

Filipe B, Baltazar C, Albuquerque C et al. APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet 2009; 76:242-55.

Filippi E, Sentinelli F, Romeo S et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age <or=50 years). J Mol Med 2005; 83:711-9.

Filippi E, Sentinelli F, Trishitta V et al. Association of the human adiponectin gene and insulin resistance. Eur J Hum Genet 2004; 12:199-205.

Filopanti M, Barbieri AM, Angioni AR et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 2008; 8:357-63.

Filopanti M, Ronchi C, Ballarè E et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:4824-8.

Filosto M, Mancuso M, Nishigaki Y et al. Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. Arch Neurol 2003; 60:1279-84.

Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 2011; 39:904-11.

Finan RR, Mustafa FE, Al-Zaman I, Madan S, Issa AA, Almawi WY. STAT3 polymorphisms linked with idiopathic recurrent miscarriages. Am J Reprod Immunol 2010; 63:22-7.

Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007; 115:2540-8.

Findling RL, Nucci G, Piergies AA et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31:1274-85.

Fingas CD, Katsounas A, Kahraman A et al. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma. Cancer Invest 2010; 28:472-8.

Finkel D, Reynolds CA, Larsson M, Gatz M, Pedersen NL. Both odor identification and ApoE-ε4 contribute to normative cognitive aging. Psychol Aging 2011. doi:10. 1037/a0023371.

Finkelstein Y, Aks SE, Hutson JR et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 2010; 48:407-14.

Finkelstein Y, Bournissen FG, Hutson JR, Shannon M. Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. J Asthma 2009; 46:900-5.

Finken MJ, Meulenbelt I, Dekker FW et al. The 23K variant of the R23K polymorphism in the glucocorticoid receptor gene protects against postnatal growth failure and insulin resistance after preterm birth. J Clin Endocrinol Metab 2007; 92:4777-82.

Finley JC Jr, O’Leary M, Wester D et al. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol 2004; 96:2231-9.

Finn RS, Dering J, Conklin D et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:77.

Finney B, Wilkinson WJ, Searchfield L et al. An exon 5-less splice variant of the extracellular calcium-sensing receptor rescues absence of the full-length receptor in the developing mouse lung. Exp Lung Res 2011; 37:269-78.

Finnström N, Ask B, Dahl ML, Gadd M, Rane A. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J 2002; 2:111-6.

Finnström N, Thörn M, Lööf L, Rane A. Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 2001; 57:403-9.

Finsterer J. Management of mitochondrial stroke-like-episodes. Eur J Neurol 2009; 16:1178-84.

Finsterer J. Perspectives of Kennedy’s disease. J Neurol Sci 2010; 298:1-10.

Finta C, Zaphiropoulos PG. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 2000; 63:433-8.

Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260:13-23.

Finta C, Zaphiropoulos PG. Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 2002; 277:5882-90.

Fiorito M, Torrente I, de Cosmo S et al. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity 2007; 15:2889-95.

Firat H, Tourdot S, Ureta-Vidal A et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur J Immunol 2001; 31:3064-74.

Firdous AP, Sindhu ER, Ramnath V, Kuttan R. Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev 2010; 11:1795-800.

Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995; 49:1777-84.

Fisas A, Codony X, Romero G et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006; 148:973-83.

Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci 1999; 884:99-109.

Fischer A, Pallauf J, Gohil K, Weber SU, Packer L, Rimbach G. Effect of selenium and vitamin E deficiency on differential gene expression in rat liver. Biochem Biophys Res Commun 2001; 285:470-5.

Fischer LM, da Costa KA, Kwock L, Galanko J, Zeisel SH. Dietary choline requirements of women: effects of estrogen and genetic variation. Am J Clin Nutr 2010; 92:1113-9.

Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408:479-83.

Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005; 14:457-77.

Fischer S, Loncar J, Zaja R et al. Constitutive mRNA expression and protein activity levels of nine ABC efflux transporters in seven permanent cell lines derived from different tissues of rainbow trout (Oncorhynchus mykiss). Aquat Toxicol 2011; 101:438-46.

Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27:410-6.

Fischer V, Vickers AE, Heitz F et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22:269-74.

Fishelovitch D, Hazan C, Hirao H, Wolfson HJ, Nussinov R, Shaik S. QM/MM study of the active species of the human cytochrome P450 3A4, and the influence thereof of the multiple substrate binding. J Phys Chem B 2007; 111:13822-32.

Fishelovitch D, Hazan C, Shaik S, Wolfson HJ, Nussinov R. Structural dynamics of the cooperative binding of organic molecules in the human cytochrome P450 3A4. J Am Chem Soc 2007; 129:1602-11.

Fishelovitch D, Shaik S, Wolfson HJ, Nussinov R. Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme: involvement of phenylalanine residues in the gating mechanism. J Phys Chem B 2009; 113:13018-25.

Fishelovitch D, Shaik S, Wolfson HJ, Nussinov R. How does the reductase help to regulate the catalytic cycle of cytochrome P450 3A4 using the conserved water channel? J Phys Chem B 2010; 114:5964-70.

Fisher CD, Lickteig AJ, Augustine LM et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37:2087-94.

Fisher E, Weikert C, Klapper M et al. L-FABP T94A is associated with fasting triglycerides and LDL-cholesterol in women. Mol Genet Metab 2007; 91:278-84.

Fisher JM, Wrighton SA, Watkins PB et al. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 1999; 289:1134-42.

Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-76.

Fisman S, Reniers D, Diaz P. Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol 1996; 6:133-8.

Fitch WL, Tran T, Young M, Liu L, Chen Y. Revisiting the metabolism of ketoconazole using accurate mass. Drug Metab Lett 2009; 3:191-8.

Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002; 277:33178-87.

Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211:361-70.

Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2005; 2(2 Suppl):30-7.

Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25:256-66.

Fitzsimmons WE, First MR. FK778, a synthetic malononitrilamide. Yonsei Med J 2004; 45:1132-5.

Flachs P, Mohamed-Ali V, Horakova O et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006; 49:394-7.

Flachsbart F, Ufer M, Kleindorp R, Nikolaus S, Schreiber S, Nebel A. Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population. J Gerontol A Biol Sci Med Sci 2011; 66:1186-91.

Flaherty KT, Lathia C, Frye RF et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1585-0.

Flanagan D. Understanding the grapefruit-drug interaction. Gen Dent 2005; 53:282-6.

Flanagan JN, Young MV, Persons KS et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res 2006; 26:2567-72.

Flanagan N, Healy E, Ray A et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 2000; 9:2531-7.

Flanagan S, Kapoor R, Banerjee I et al. Dominantly acting ABCC8 mutations in patients with medically unresponsive hyperinsulinaemic hypoglycaemia. Clin Genet 2011; 79:582-7.

Flanagan SE, Clauin S, Bellanné-Chantelot C et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6. 2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009; 30:170-80.

Flanagan SE, Kapoor RR, Mali G et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol 2010; 162:987-92.

Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 2008; 13:3648-60.

Flavell DM, Jamshidi Y, Hawe E et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105:1440-5.

Flechtner I, de Lonlay P, Polak M. Diabetes and hypoglycaemia in young children and mutations in the Kir6. 2 subunit of the potassium channel: therapeutic consequences. Diabetes Metab 2006; 32:569-80.

Fleeman N, Dundar Y, Dickson R et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011; 11:1-14.

Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39:413-27.

Fleishaker JC, Herman BD, Carel BJ, Azie NE. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003; 43:423-7.

Fleishaker JC, Pearson LK, Pearson PG, Wienkers LC, Hopkins NK, Peters GR. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. J Clin Pharmacol 1999; 39:260-7.

Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation. J Pharmacol Exp Ther 1998; 287:591-7.

Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67:498-503.

Fleisher AS, Raman R, Siemers ER et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65:1031-8.

Flekac M, Skrha J, Hilgertova J, Lacinova Z, Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med Genet 2008; 9:30.

Fletcher B, Goldstein DB, Bradman AL, Weale ME, Bradman N, Thomas MG. High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics 2003; 81:166-74.

Fleury I, Primeau M, Doreau A et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics 2004; 4:331-41.

Flint MS, Hood BL, Sun M, Stewart NA, Jones-Laughner J, Conrads TP. Proteomic analysis of the murine liver in response to a combined exposure to psychological stress and 7,12-dimethylbenz(a)anthracene. J Proteome Res 2010; 9:509-20.

Flockhart DA, Drici MD, Kerbusch T et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20:317-24.

Flockhart DA, O’Kane D, Williams MS et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10:139-50.

Flomen R, Knight J, Sham P, Kerwin R, Makoff A. Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res 2004; 32:2113-22.

Flordellis C, Manolis A, Scheinin M, Paris H. Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 2004; 97:367-72.

Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62:41-9.

Flores-Dorantes T, Arellano-Campos O, Posadas-Sánchez R et al. Association of R230C ABCA1 gene variant with low HDL-C levels and abnormal HDL subclass distribution in Mexican school-aged children. Clin Chim Acta 2010; 411:1214-7.

Flores-Murrieta FJ, Carrasco-Portugal MdelC, Landa C. Comparison of the oral pharmacokinetics of fluconazole and itraconazole in Mexicans. Proc West Pharmacol Soc 2008; 51:63-5.

Florez JC, Burtt N, de Bakker PI et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004; 53:1360-8.

Florez JC, Jablonski KA, Sun MW et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocr Metab 2007; 92:1502-9.

Floyd MD, Gervasini G, Masica AL et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13:595-606.

Flück CE, Mallet D, Hofer G et al. Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. Biochem Biophys Res Commun 2011; 412:572-7.

Flück CE, Pandey AV. Clinical and biochemical consequences of p450 oxidoreductase deficiency. Endocr Dev 2011; 20:63-79.

Fluhrer R, Friedlein A, Haass C, Walter J. Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. J Biol Chem 2004; 279:1585-93.

Fogarasi M, Janssen A, Weber BH, Stöhr H. Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Matrix Biol 2008; 27:381-92.

Fogelman SM, Schmider J, Venkatakrishnan K et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20:480-90.

Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-59.

Fojo A, Lebo R, Shimizu N et al. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Molec Genet 1986; 12:415-20.

Fojtíková M, Stolfa J, Novota P, Cejková P, Dostál C, Cerná M. HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population. Rheumatol Int 2009; 29:1293-9.

Fokina VM, Patrikeeva SL, Zharikova OL, Nanovskaya TN, Hankins GV, Ahmed MS. Transplacental transfer and metabolism of buprenorphine in preterm human placenta. Am J Perinatol 2011; 28:25-32.

Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6:1249-65.

Folsom AR, Peacock JM, Boerwinkle E, Cushman M. beta2-adrenergic receptor polymorphism and venous thromboembolism. Thromb Haemost 2008; 99:240.

Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73:363-70.

Fong CS, Shyu HY, Shieh JC et al. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson’s disease among ethnic Chinese in Taiwan. Clin Chim Acta 2011; 412:332-8.

Fong CS, Wu RM, Shieh JC et al. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson’s disease. Clin Chim Acta 2007; 378:136-41.

Fonsart J, Menet MC, Debray M et al. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). Toxicol Appl Pharmacol 2009; 241:339-47.

Fonseca F, de la Torre R, Díaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 2011. doi:10. 1371/journal. pone. 0019527.

Fontaine SM, Hoyer PB, Halpert JR, Sipes IG. Role of induction of specific hepatic cytochrome P450 isoforms in epoxidation of 4-vinylcyclohexene. Drug Metab Dispos 2001; 29:1236-42.

Fontana L, Delort L, Joumard L et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res 2009; 29:1631-5.

Fontana P, Dupont A, Gandrille S et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y(12) gene sequence variations in healthy subjects. Circulation 2003; 108:989-95.

Fontana P, Gandrille S, Remones V et al. Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thromb Haemost 2006; 3:356-60.

Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y(12) H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108:2971-73.

Fontana P, Remones V, Reny JL, Aiach M, Gaussem P. P2Y1 gene polymorphism and ADP-induced platelet response. J Thromb Haemost 2005; 3:2349-50.

Fontana RJ, Lown KS, Paine MF et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999; 117:89-98.

Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23:1429-35.

Fontanière S, Duvillié B, Scharfmann R, Carreira C, Wang ZQ, Zhang CX. Tumour suppressor menin is essential for development of the pancreatic endocrine cells. J Endocrinol 2008; 199:287-98.

Foote KM, Mortlock AA, Heron NM et al. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorg Med Chem Lett 2008; 18:1904-9.

Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 2000; 50:77-80.

Ford NF. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 2009; 49:506-12.

Ford SL, Chen YC, Lou Y et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 2008; 52:534-8.

Forero DA, Arboleda GH, Vasquez R, Arboleda H. Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. J Psychiatry Neurosci 2009; 34:361-6.

Foresta C, Strapazzon G, de Toni L et al. Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J Clin Endocrinol Metab 2011; 96:646-52.

Forget B, Wertheim C, Mascia P, Pushparaj A, Goldberg SR, Le Foll B. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 2010; 35:1751-60.

Forget P, le Polain de Waroux B, Wallemacq P, Gala JL. Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. J Pain Symptom Manage 2008; 36:92-6.

Forkert PG. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 2010; 42:355-78.

Forleo C, Resta N, Sorrentino S et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004; 117:451-8.

Forleo C, Sorrentino S, Guida P et al. Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med 2007; 8:589-95.

Forman MS, Lee VM, Trojanowski JQ. New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. J Chem Neuroanat 2000; 20:225-44.

Formanack ML, Baier LJ. Variation in the FABP2 promoter affects gene expression: implications for prior association studies. Diabetologia 2004; 47:349-51.

Fornage M, Turner ST, Sing CF, Boerwinkle E. Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet 1995; 96:295-300.

Fornier MN, Rathkopf D, Shah M et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841-6.

Forrest GL, Gonzalez B. Carbonyl reductase. Chem Biol Interact 2000; 129:21-40.

Forsberg L, Leeb L, Thoren S, Morgenstern R, Jakobsson PJ. Human glutathione dependent prostaglandin E synthase: gene structure and regulation. FEBS Lett 2000; 471:78-82.

Forti G, Falchetti A, Santoro S, Davis DL, Wilson JD, Russell DW. Steroid 5 alpha-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clin Endocrinol 1996; 44:477-82.

Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 2007; 7:352-6.

Foster AE, Okur FV, Biagi E et al. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 2010; 24:563-72.

Foster BC, Arnason JT, Saleem A et al. Comparative study of hops-containing products on human cytochrome P450-mediated metabolism. J Agric Food Chem 2011; 59:5159-63.

Foster BC, Kearns N, Arnason JT, Saleem A, Ogrodowczyk C, Desjardins S. Comparative study of hop-containing products on human cytochrome p450-mediated metabolism. J Agric Food Chem 2009; 57:5100-5.

Foster CB, Lehrnbecher T, Samuels S et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96:2562-7.

Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 1985; 82:4673-7.

Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47:403-12.

Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50:427-40.

Foster PP, Rosenblatt KP, Kuljiš RO. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer’s disease. Front Neurol 2011; 2:28.

Foti RS, Dickmann LJ, Davis JA et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008; 38:264-80.

Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies Using in vitro data and in vivo simulation. Drug Metab Dispos 2010; 38:981-7.

Fotoohi AK, Assaraf YG, Moshfegh A et al. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol 2009; 77:1410-7.

Fotsch C, Bartberger MD, Bercot EA et al. Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J Med Chem 2008; 51:7953-67.

Foucher C, Rattier S, Flavell DM et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004; 14:823-9.

Fouladi M, Nicholson HS, Zhou T et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group study. Cancer 2007; 110:2535-41.

Fournier B, Saudubray JM, Benichou B et al. Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy. J Clin Invest 1994; 94:526-31.

Fowler EV, Eri R, Hume G et al. TNF-alpha and IL10 SNPs act together to predict disease behaviour in Crohn’s disease. J Med Genet 2005; 42:523-8.

Fowler JH, Settle JE, Christakis NA. Correlated genotypes in friendship networks. Proc Natl Acad Sci USA 2011; 108:1993-7.

Fowler JS, Volkow ND, Wang GJ et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379:733-6.

Fowler SJ, Hall IP, Wilson AM, Wheatley AP, Lipworth BJ. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002; 58:187-90.

Fowler SM, Riley RJ, Pritchard MP, Sutcliffe MJ, Friedberg T, Wolf CR. Amino acid 305 determines catalytic center accessibility in CYP3A4. Biochemistry 2000; 39:4406-14.

Fowler SM, Taylor JM, Friedberg T, Wolf CR, Riley RJ. CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metab Dispos 2002; 30:452-6.

Fox CS, Yang Q, Cupples LA et al. Sex-specific association between estrogen receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90:6257-62.

Foxenberg RJ, Ellison CA, Knaak JB, Ma C, Olson JR. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. Toxicology 2011; 285:57-66.

Fradin S, Goulet-Salmon B, Chantepie M et al. Relationship between polymorphisms in the renin-angiotensin system and nephropathy in type 2 diabetic patients. Diabetes Metab 2002; 28:27-32.

Fraering PC, Ye W, Strub JM et al. Purification and characterization of the human gamma-secretase complex. Biochemistry 2004; 43:9774-89.

Fraga AG, da Silva LL, Fraga CA, Barreiro EJ. CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. Eur J Med Chem 2011; 46:349-55.

Fragoso JM, Delgadillo H, Juárez-Cedillo T et al. The interleukin 6 -572 G>C (rs1800796) polymorphism is associated with the risk of developing acute coronary syndrome. Genet Test Mol Biomarkers 2010; 14:759-63.

Fragoso JM, Rodríguez-Pérez JM, González J et al. Beta1-adrenergic receptor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 2006; 80:279-82.

Frampton GA, Lazcano EA, Li H, Mohamad A, DeMorrow S. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 2010; 90:1325-38.

Francis R, McGrath G, Zhang G et al. Aph-1 and pen-2 are required for Notch pathway signalling, gamma-secretase cleavage of beta-APP, and presenilin protein accumulation. Dev Cell 2002; 3:85-97.

Franco E, Palumbo L, Crobu F et al. Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. BMC Med Genet 2007; 8:27.

Francois AA, Nishida CR, de Montellano PR, Phillips IR, Shephard EA. Human flavin-containing monooxygenase 2. 1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos 2009; 37:178-86.

Francois J. Retinoblastoma and osteogenic sarcoma. Ophthalmologica 1977; 175:185-91.

Franco-Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 2010; 49:177-88.

Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63:321-33.

Frank D, Kuhn C, van Eickels M et al. Calsarcin-1 protects against angiotensin-II-induced cardiac hypertrophy. Circulation 2007; 116:2587-96.

Frank DJ, Denisov IG, Sligar SG. Mixing apples and oranges: Analysis of heterotropic cooperativity in cytochrome P450 3A4. Arch Biochem Biophys 2009; 488:146-52.

Frank H, Gröger N, Diener M, Becker C, Braun T, Boettger T. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J Biol Chem 2008; 283:24729-37.

Franke A, Balschun T, Karlsen TH et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40:1319-23

Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008; 84:704-9.

Franke RM, Lancaster CS, Peer CJ et al. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther 2011; 89:693-701.

Frankfort SV, Doodeman VD, Bakker R et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener 2006; 1:13.

Franklin MR, Constance JE. Comparative 1-substituted imidazole inhibition of cytochrome p450 isozyme-selective activities in human and mouse hepatic microsomes. Drug Metab Rev 2007; 39:309-22.

Franklin MR, Hathaway LB. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab Dispos 2008; 36:2539-46.

Franklin TR, Wang Z, Li Y et al. Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol 2011; 16:308-22.

Franko A, Dolzan V, Arnerić N, Dodic-Fikfak M. The influence of genetic polymorphisms of GSTP1 on the development of asbestosis. J Occup Environ Med 2008; 50:7-12.

Fransson MN, Gréen H, Litton JE, Friberg LE. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 2011; 39:247-55.

Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008; 5:1557-66.

Franzellitti S, Buratti S, Valbonesi P, Capuzzo A, Fabbri E. The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquat Toxicol 2011; 101:299-308.

Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 2007; 81:828-32.

Frayling TM. Commentary: Genetic association studies see light at the end of the tunnel. Int J Epidemiol 2008; 37:133-5.

Frech MS, Torre KM, Robinson GW, Furth PA. Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene 2008; 27:3186-93.

Frederick KS, Maurer TS, Kalgutkar AS et al. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Xenobiotica 2009; 39:766-81.

Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 2003; 3:291-301.

Frederiksen L, Brødbaek K, Fenger M et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87:3989-92.

Frederiksen L, Brødbaek K, Fenger M et al. No interactions between polymorphisms in the beta3-adrenergic receptor gene and the PPAR-gamma gene on the risk of the insulin resistance syndrome in the Danish MONICA cohort. Diabetologia 2003; 46:729-31.

Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000; 362:364-74.

Freedman RS, Wang E, Voiculescu S et al. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 2007; 13:5736-44.

Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res 2008; 52:789-98.

Freeman DJ, Juan T, Reiner M et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7:184-90.

Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 2002; 64:289-95.

Freigang S, Ampenberger F, Spohn G et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011; 41:2040-51.

Freimuth RR, Xiao M, Marsh S et al. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet 2005; 14:3595-603.

Freitas AI, Mendonça I, Brión M et al. RAS gene polymorphisms, classical risk factors and the advent of coronary artery disease in the Portuguese population. BMC Cardiovasc Disord 2008; 8:15.

Freitas RF, Bauab RL, Montanari CA. Novel application of 2D and 3D-similarity searches to identify substrates among cytochrome P450 2C9, 2D6, and 3A4. J Chem Inf Model 2010; 50:97-109.

Freitas RN, Khaw KT, Wu K et al. HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study. Eur J Cardiovasc Prev Rehabil 2010; 17:89-93.

Frémin C, Ezan F, Guegan JP et al. The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses. J Cell Physiol 2011. doi:10. 1002/jcp. 22742.

Fremont JJ, Wang RW, King CD. Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. Mol Pharmacol 2005; 67:260-2.

French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, Azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I (PAI-I) protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58:143-8.

Frere C, Cuisset T, Morange PE et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101:1088-93.

Freson K, Jaeken J, van Helvoirt M et al. Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum Mol Genet 2003; 12:1121-30.

Frey UH, Alakus H, Wohlschlaeger J, et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005; 11:5071-7.

Frey UH, Hauner H, Jöckel KH, Manthey I, Brockmeyer N, Siffert W. A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. Pharmacogenet Genomics 2008; 18:141-51.

Frey UH, Lümmen G, Jäger T et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006; 12:759-63.

Friederich P, Solth A, Schillemeit S, Isbrandt D. Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1 T8A. Br J Anaesth 2004; 92:93-101.

Friedland G, Andrews L, Schreibman T et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635-41.

Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011; 36:17-24.

Frikke-Schmidt R, Nordestgaard BG, Thudium D, Moes Gronholdt ML, Tybjaerg-Hansen A. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology 2001; 56:194-200.

Frikke-Schmidt R, Sing CF, Nordestgaard BG, Steffensen R, Tybjaerg-Hansen A. Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Hum Genet 2007; 120:865-77.

Frisoni GB, Geroldi C, Bianchetti A et al. Apolipoprotein E epsilon-4 allele frequency in vascular dementia and Alzheimer’s disease. Stroke 1994; 25:1703.

Fritz HG, Holzmayr M, Walter B, Moeritz KU, Lupp A, Bauer R. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg 2005; 100:996-1002.

Fritze F, Ehrt U, Sønnesyn H et al. Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry 2011; 26:1054-61.

Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 2010; 24:99-117.

Fröhlich E, Kueznik T, Samberger C, Roblegg E, Wrighton C, Pieber TR. Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol 2010; 242:326-32.

Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 2006; 117:310-8.

Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54:1295-310.

Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002; 181-2:299-303.

Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24:796-801.

Fromm MF, Eckhardt K, Li S et al. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 1997; 72:261-7.

Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007; 17:695-707.

Fruttero R, Crosetti M, Chegaev K et al. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J Med Chem 2010; 53:5467-75.

Fry DW, Harvey PJ, Keller PR et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38.

Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol 2002; 53:155-62.

Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76:323-9.

Frye RF, Tammara B, Cowart TD, Bramer SL. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. J Clin Pharmacol 1999; 39:1177-83.

Frye RF, Zgheib NK, Matzke GR et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006; 80:235-45.

Fu AL, Zhou CY, Chen X. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer’s disease. Neuropharmacology 2010; 58:722-9.

Fu L, Zhao Y, Wu X et al. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res 2011; 34:722-7.

Fu M, Kazlauskaite R, Baracho MdeF et al. Mutations in Gng31g and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects. J Clin Endocr Metab 2004; 89:2916-22.

Fu Y, Fan CH, Deng HH et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27:328-32.

Fu Y, He F, Tang NL et al. NEDD9 gene polymorphism influences the risk of Alzheimer disease and cognitive function in Chinese older persons. Alzheimer Dis Assoc Disord 2011. doi:10. 1097/WAD. 0b013e3182135ef3.

Fu Z, Nakayama T, Sato N et al. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens 2008; 21:1216-23.

Fu Z, Nakayama T, Sato N et al. Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects. Hypertens Res 2008; 31:1719-26.

Fu Z, Nakayama T, Sato N et al. A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab 2009; 96:145-7.

Fu Z, Regan K, Zhang L et al. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest 2009; 119:2714-24.

Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394:1098-104.

Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998; 18:251-72.

Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007; 73:1429-35.

Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 57:595-601.

Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 2007; 81:270-83.

Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H. Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther 2005; 43:327-34.

Fujihara J, Fujii Y, Agusa T et al. Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol Appl Pharmacol 2009; 234:41-6.

Fujihara J, Kunito T, Agusa T et al. Population differences in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene polymorphism detected by using genotyping method. Toxicol Appl Pharmacol 2007; 225:251-4.

Fujihara J, Soejima M, Koda Y, Kunito T, Takeshita H. Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat Res 2008; 654:158-61.

Fujihara J, Soejima M, Yasuda T et al. Global analysis of genetic variation in human arsenic (+3 oxidation state) methyltransferase (AS3MT). Toxicol Appl Pharmacol 2010; 243:292-9.

Fujii Y, Kabumoto H, Nishimura K et al. Purification, characterization, and directed evolution study of a vitamin D3 hydroxylase from Pseudonocardia autotrophica. Biochem Biophys Res Commun 2009; 385:170-5.

Fujii Y, Shibata H, Kikuta R et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003; 13:71-6.

Fujimaki Y, Arai N, Nakazawa T, Fujimaki M. Nefiracetam metabolism by human liver microsomes: role of cytochrome P450 3A4 and cytochrome P450 1A2 in 5-hydroxynefiracetam formation. J Pharm Pharmacol 2001; 53:795-804.

Fujimaki Y, Hakusui H, Yamazoe Y. Nefiracetam hydroxylation by rat liver microsomes and expressed human cytochrome P450s. Xenobiotica 1996; 26:821-30.

Fujimura H, Murakami N, Miwa S, Aruga C, Toriumi W. The suitability of rat hepatoma cell line H4IIE for evaluating the potentials of compounds to induce CYP3A23 expression. Exp Toxicol Pathol 2010. doi:10. 1016/j. etp. 2010. 11. 010.

Fujimura T, Takahashi S, Urano T et al. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009; 74:391-7.

Fujino H, Saito T, Tsunenari Y, Kojima J. Interaction between several medicines and statins. Arzneimittelforschung 2003; 53:145-53.

Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004; 34:961-71.

Fujino H, Yamada I, Shimada S, Hirano M, Tsunenari Y, Kojima J. Interaction between fibrates and statins-metabolic interactions with gemfibrozil. Drug Metabol Drug Interact 2003; 19:161-76.

Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002; 52:745-53.

Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003; 33:27-41.

Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004; 20:195-217.

Fujita K, Ando Y, Nagashima F et al. Novel single nucleotide polymorphism of UGT1A7 gene in Japanese. Drug Metab Pharmacokinet 2006; 21:75-8.

Fujita K, Ando Y, Narabayashi M et al. Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan. Drug Metab Dispos 2005; 33:1785-90.

Fujita K, Kamataki T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab Dispos 2001; 29:983-9.

Fujita K, Kamataki T. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 2001; 38:339-46.

Fujita K, Kamataki T. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res 2001; 483:35-41.

Fujita K, Nagashima F, Yamamoto W et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) Biol Pharm Bull 2008; 31:2137-42.

Fujita K, Nakayama K, Yamazaki Y et al. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 2001; 38:329-38.

Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 2011; 67:237-41.

Fujita T, Kawase A, Niwa T et al. Comparative evaluation of 12 immature citrus fruit extracts for the inhibition of cytochrome P450 isoform activities. Biol Pharm Bull 2008; 31:925-30.

Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 2001; 48:42-6.

Fujiwara H, Tatsumi K, Miki K et al. Recurrent T354P mutation of the Na+/I- symporter in patients with iodide transport defect. J Clin Endocrinol Metab 1998; 83:2940-3.

Fujiwara Y, Ichihashi M, Kano Y, Goto K, Shimizu K. A new human photosensitive subject with a defect in the recovery of DNA synthesis after ultraviolet-light irradiation. J Invest Dermatol 1981; 77:256-63.

Fukami M, Shozu M, Soneda S et al. Aromatase excess syndrome: identification of cryptic duplications and deletions leading to gain of function of CYP19A1 and assessment of phenotypic determinants. J Clin Endocrinol Metab 2011; 96:1035-43.

Fukami T, Nakajima M, Higashi E et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 2005; 33:1202-10.

Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 2005; 70:801-8.

Fukami T, Nakajima M, Matsumoto I, Zen Y, Oda M, Yokoi T. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 2010; 101:1024-8.

Fukami T, Nakajima M, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 2007; 35:515-20.

Fukami T, Nakajima M, Yoshida R et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004; 76:519-27.

Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32:333-41.

Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K. Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Ther Drug Monit 2004; 26:529-33.

Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. Eur J Clin Pharmacol 2005; 61:791-5.

Fukazawa T, Yajima K, Miyamoto Y. Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi 2008; 128:1459-65.

Fukuda D, Enomoto S, Hirata Y, Nagai R, Sata M. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. Biomed Pharmacother 2010; 64:712-7.

Fukuda K, Guo L, Ohashi N, Yoshikawa M, Yamazoe Y. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr B Biomed Sci Appl 2000; 741:195-203.

Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7:391-6.

Fukuda T, Nishida Y, Imaoka S et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000; 380:303-8.

Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56:175-80.

Fukuda T, Onishi S, Fukuen S et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004; 4:34-9.

Fukuda Y, Aguilar-Bryan L, Vaxillaire M et al. Conserved intramolecular disulfide bond is critical to trafficking and fate of ATP-binding cassette (ABC) transporters ABCB6 and sulfonylurea receptor 1 (SUR1)/ABCC8. J Biol Chem 2011; 286:8481-92.

Fukudo M, Yano I, Masuda S et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006; 80:331-45.

Fukudo M, Yano I, Yoshimura A et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18:413-23.

Fukuen S, Fukuda T, Matsuda H et al. Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 2002; 298:433-8.

Fukui N, Suzuki Y, Sawamura K et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 2007; 29:185-9.

Fukumori S, Murata T, Taguchi M, Hashimoto Y. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells. Drug Metab Pharmacokinet 2007; 22:377-81.

Fukumoto K, Kobayashi T, Tachibana K et al. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 2006; 21:501-5.

Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004; 4:307-14.

Fukunaga-Kalabis M, Martinez G, Nguyen TK et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010; 29:6115-24.

Fukushima M, Han KH, Taneichi Y et al. Amylomyces rouxii strain CBS 438. 76 affects cholesterol metabolism in cholesterol-fed rats. J Nutr Sci Vitaminol 2005; 51:453-9.

Fukushima-Uesaka H, Maekawa K, Ozawa S et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 2004; 19:239-44.

Fukushima-Uesaka H, Saito Y, Maekawa K et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:300-7.

Fukushima-Uesaka H, Saito Y, Maekawa K et al. Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet 2009; 24:565-74.

Fukushima-Uesaka H, Saito Y, Tohkin M et al. Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population. Drug Metab Pharmacokinet 2007; 22:48-60.

Fukushima-Uesaka H, Saito Y, Watanabe H et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23:100.

Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother 2010; 44:377-82.

Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008; 28:945-9.

Funakoshi N, Duret C, Pascussi JM et al. Comparison of hepatic-like cell production from human embryonic stem cells and adult liver progenitor cells: CAR transduction activates a battery of detoxification genes. Stem Cell Rev 2011; 7:518-31.

Funck-Brentano C, Becquemont L, Kroemer HK et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55:256-69.

Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280:730-8.

Funck-Brentano C, Boëlle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005; 61:821-9.

Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther 2000; 22:549-72.

Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794:860-71.

Fung Y-KT, Murphree AL, T’Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236:1657-61.

Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59:627-35.

Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871-5.

Funke B, Finn CT, Plocik AM et al. Association of the DTNBP1 locus with schizophrenia in a U. S. population. Am J Hum Genet 2004; 75:891-8.

Furman KD, Grimm DR, Mueller T et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004; 14:279-84.

Furnes B, Schlenk D. Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol Sci 2004; 78:196-203.

Fürnrohr BG, Wach S, Kelly JA et al. Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:1983-9.

Furster C, Wikvall K. Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol in human liver microsomes. Biochim Biophys Acta 1999; 1437:46-52.

Furukawa M, Okubo T, Ogino M et al. Adenovirus vector-mediated reporter system for in vivo analyses of human CYP3A4 gene activation. J Biochem 2002; 131:71-8.

Furukawa Y, Kish SJ, Bebin EM et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol 1998; 44:10-6.

Furukori H. Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol. Nihon Shinkei Seishin Yakurigaku Zasshi 1998; 18:9-14.

Furukori H, Kondo T, Yasui N et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology 1999; 145:189-92.

Furukori H, Otani K, Yasui N et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 1998; 18:364-9.

Furumatsu K, Nishiumi S, Kawano Y et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci 2011; 56:2532-44.

Furumiya K, Mizutani T. Inhibition of human CYP3A4, UGT1A6, and P-glycoprotein with halogenated xanthene food dyes and prevention by superoxide dismutase. J Toxicol Environ Health A 2008; 71:1307-13.

Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66:6080-6.

Furuta K, Adachi K, Ohara S et al. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study. J Int Med Res 2010; 38:1473-83.

Furuta S, Akagawa N, Kamada E et al. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br J Clin Pharmacol 2002; 54:295-303.

Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Nat Acad Sci USA 2005; 102:9176-81.

Furuta S, Kamada E, Omata T et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol 2004; 497:223-31.

Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70:383-92.

Furuta T, Kodaira C, Nishino M et al. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30:294-300.

Furuta T, Ohashi K, Kobayashi K et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999; 66:265-74.

Furuta T, Shirai N, Kodaira M et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81:521-8.

Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72:453-60.

Furuta T, Sugimoto M, Kodaira C et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol 2009; 65:693-8.

Furuyama S, Uehara Y, Zhang B et al. Genotypic effect of ABCG1 gene promoter -257T>G polymorphism on coronary artery disease severity in Japanese men. J Atheroscler Thromb 2009; 16:194-200.

Fuse I, Mito M, Hattori A et al. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A2 activation. Blood 1993; 81:994-1000.

Fuse N, Miyazawa A, Takahashi K, Noro M, Nakazawa T, Nishida K. Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population. Jpn J Ophthalmol 2010; 54:1-6.

Fuselli S, Dupanloup I, Frigato E et al. Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 2004; 12:916-24.

Fuso A, Seminara L, Cavallaro RA, D’Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005; 28:195-204.

Fustier P, Le Corre L, Chalabi N et al. Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. Br J Cancer 2003; 89:168-72.

Fux R, Mörike K, Pröhmer AM et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005; 78:378-87.

Fyrberg A, Peterson C, Kågedal B, Lotfi K. Induction of fetal hemoglobin and ABCB1 gene expression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2011; 68:583-91.